Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis (NVS) Projected to Post Quarterly Earnings on Tuesday
02:26am, Sunday, 26'th Oct 2025
Novartis (NYSE: NVS - Get Free Report) will likely be announcing its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect the company to announce earnings of $2.28 per sha
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
11:00am, Saturday, 25'th Oct 2025
Basel, October 25, 2025 – Novartis announced today plans to present data from 27 company- or investigator-sponsored abstracts across its Immunology portfolio and pipeline at the 2025 American Colleg
Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics
10:16am, Thursday, 23'rd Oct 2025
Besides Wall Street's top-and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qua
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Thursday, 23'rd Oct 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Wednesday, 22'nd Oct 2025
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
Novartis AG (NYSE:NVS) Receives Average Recommendation of “Hold” from Analysts
01:20am, Wednesday, 22'nd Oct 2025
Novartis AG (NYSE: NVS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten research firms that are covering the stock, Marketbeat Ratings reports. Three analysts hav
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
01:15am, Wednesday, 22'nd Oct 2025
Basel, October 22, 2025 – Novartis today announced that Cosentyx® (secukinumab) met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial1. Cosentyx demonstrated statis
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
01:00am, Wednesday, 22'nd Oct 2025
Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection w
Novartis' Pluvicto shown to reduce risk of progression or death by 28% in prostate cancer
10:56am, Sunday, 19'th Oct 2025
Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death in patients with prostate cancer by 28%.
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
10:30am, Sunday, 19'th Oct 2025
Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Socie
Basel, October 17, 2025 – Novartis today announced results from the five-year analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that demonstrated a sustained benefit at a med
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
06:37am, Friday, 17'th Oct 2025
Basel, October 17, 2025 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommende
Novartis: Assessing The Impact Of Entresto Generics
01:23pm, Thursday, 16'th Oct 2025
Entresto generics have finally arrived in the U.S. in July, and approximately 9% of Novartis' revenue will be impacted. The growth of other key products and of Entresto in ex-U.S. territories should b
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
09:51am, Thursday, 16'th Oct 2025
Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.
Novartis' Fabhalta slows progression of rare kidney disease in trial
01:40am, Thursday, 16'th Oct 2025
Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial.
